Sorafenib in Hepatocellular Carcinoma clinical practice in Italy (STELLA)
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.
- Patients with histologically/cytologically confirmed HCC or radiographically diagnosed as per AASLD criteria, who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made - Patients must have signed the informed consent form - Patients must have a life expectancy of at least 8 weeks Inclusion criteria must follow the approved local product information.
- Prior treatment with sorafenib - Concomitant participation in other clinical studies Exclusion criteria must follow the approved local product information.
Many Locations, Italy
E-mail: [email protected]
Phone: Not Available
Sorafenib Treatment modalities for HEpatoceLLular Carcinoma patients in ItAly